Opioid-Sparing Joint Replacement Study
This study is looking at whether a pain management plan that uses fewer opioids (pain medications like oxycodone) can still effectively control pain after total hip replacement surgery for osteoarthritis. All participants will receive a standard non-opioid pain regimen, including medications like acetaminophen and meloxicam, along with spinal anesthesia and local anesthetic injections. Some participants will also receive 5 mg oxycodone tablets, while others will receive identical-looking placebo tablets. The researchers want to see if limiting routine opioid prescriptions can reduce how much opioid medication you use without making your pain worse or affecting your satisfaction. You might be able to join if you are an adult having total hip replacement surgery for hip osteoarthritis and can follow study procedures. The study will measure your daily pain, how much opioid medication you use, and how often you contact your care team about pain for up to three months after surgery. The current recruitment status is unclear.
- Study design
- This is a randomized, double-blind study, meaning participants are randomly assigned to a treatment group and neither you nor your doctors will know which treatment you are receiving. It plans to enroll 120 participants.
- What's involved
- You will receive a standardized pain regimen and counseling. Your pain scores, nausea, opioid use, and other outcomes will be collected during the first week after surgery and at follow-up visits at 3 weeks and 3 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 3 months after surgery to assess pain-related contacts to the clinical team.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Opioid-Sparing Joint Replacement
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Ajay Premkumar, MD · PRINCIPAL_INVESTIGATOR · Emory University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Daily Pain Scores (Numeric Rating Scale, NRS)Postoperative Days 1-7
A 0-10 numeric scale used to assess pain intensity. Participants rate their pain three times daily during the first postoperative week. Mean daily pain scores will be compared between groups. High scores: greater pain intensity. Low scores: better pain control.
- Opioid Consumption (Morphine Milligram Equivalents, MME)1 week, 3 weeks, and 3 months postoperatively
Total opioid use, including study medication, rescue hydromorphone, and any additional prescriptions, will be converted to MME to quantify postoperative opioid consumption.
- Pain-Related Contacts to Clinical TeamUp to 3 months postoperatively
Number of calls or electronic messages to the surgical team related to pain management.
- Medication-Related Side EffectsPostoperative Days 1-7
Incidence and severity of nausea, constipation, vomiting, or other adverse effects associated with postoperative pain medications.
- Opioid Prescription RefillsUp to 3 months postoperatively
Number of opioid prescription refills requested or obtained after surgery.
- Patient Satisfaction With Pain Control1 week, 3 weeks, and 3 months
Patient-reported satisfaction with postoperative pain control, rated on a 5-point scale (much worse than expected to much better than expected).